Idorsia’s Aprocitentan Shows Kidney, Cardiovascular Benefits in Resistant Hypertension
Event summary
- Idorsia’s aprocitentan significantly reduced albuminuria in patients with resistant hypertension, per new PRECISION study data presented at the 35th ESH Congress.
- By Week 36, aprocitentan reduced mean UACR from 77.5 mg/g to 34 mg/g in microalbuminuria patients and from 860.2 mg/g to 286.7 mg/g in macroalbuminuria patients.
- Approximately 46% of patients with baseline micro- or macroalbuminuria achieved a lower albuminuria risk category by Week 36.
- Aprocitentan demonstrated stable eGFR and no hyperkalemia risk, addressing a critical unmet need in resistant hypertension.
The big picture
Idorsia’s aprocitentan is positioning itself as a key player in resistant hypertension management, addressing a critical gap in treating patients with chronic kidney disease and type 2 diabetes. The drug’s ability to reduce albuminuria and stabilize eGFR without electrolyte disturbances could reshape treatment paradigms, particularly as hypertension remains the leading modifiable risk factor for cardiovascular disease. The strategic focus on endothelin pathway inhibition differentiates aprocitentan from RAAS pathway therapies, potentially expanding its market reach.
What we're watching
- Therapeutic Differentiation
- Whether aprocitentan’s endothelin pathway inhibition can sustain long-term renal and cardiovascular benefits in resistant hypertension.
- Regulatory Expansion
- The pace at which aprocitentan gains approvals beyond the US and Europe, particularly in Canada.
- Market Adoption
- How the absence of hyperkalemia risk influences prescribing behavior in high-risk patient populations.
Related topics